emerg
sever
acut
respiratori
syndrom
coronaviru
sarscov
led
rapid
respons
contain
outbreak
also
identifi
possibl
therapeut
intervent
includ
gener
human
monoclon
antibodi
hmab
human
mab
may
use
therapeut
without
drawback
chimer
anim
ab
sever
differ
method
use
gener
sarscov
specif
neutral
hmab
includ
immun
transgen
mice
clone
small
chain
variabl
region
convalesc
patient
immort
convalesc
b
cell
irrespect
techniqu
use
major
hmab
specif
react
receptor
bind
domain
rbd
spike
protein
like
prevent
receptor
bind
howev
sever
hmab
bind
epitop
either
within
rbd
locat
n
termin
rbd
domain
neutral
viru
without
inhibit
receptor
bind
identifi
therapeut
util
hmab
elucid
identif
potenti
combin
hmab
could
neutral
viral
variant
includ
escap
mutant
select
use
hmab
result
suggest
cocktail
hmab
bind
uniqu
epitop
differ
mechan
action
might
clinic
util
sarscov
infect
indic
similar
approach
may
appli
treat
viral
infect
sever
acut
respiratori
syndrom
coronaviru
sarscov
identifi
member
coronavirida
follow
outbreak
acut
respiratori
syndrom
follow
sever
superspread
event
end
outbreak
juli
sarscov
infect
respons
death
case
worldwid
involv
countri
viru
isol
recov
individu
repres
second
zoonot
event
indic
continu
threat
sarscov
reentri
human
molecular
analysi
sarscov
outbreak
group
virus
earli
middl
late
isol
earli
isol
exhibit
greater
sequenc
divers
suggest
molecular
evolut
occur
outbreak
patient
infect
sarscov
show
atyp
pneumonia
sever
lung
damag
sarscov
infect
type
type
ii
pneumocyt
epitheli
cell
line
alveolu
lung
diseas
progress
accompani
influx
inflammatori
infiltr
lung
approxim
patient
develop
acut
respiratori
distress
syndrom
ard
roughli
half
individu
ard
die
anoth
uniqu
featur
sarscov
rel
known
cov
tissu
distribut
infect
individu
sarscov
caus
system
infect
sever
patholog
lung
sarscov
also
replic
epitheli
cell
intestin
viral
rna
recov
kidney
liver
tissu
genom
analys
epidemiolog
data
identifi
palm
civet
intermedi
host
sar
outbreak
sarslikecov
isol
two
independ
group
chines
horsesho
bat
bat
serv
reservoir
group
group
cov
sarscov
classifi
group
anoth
sarscov
outbreak
observ
howev
second
introduct
sarscov
continu
presenc
viru
anim
reservoir
indic
human
infect
could
occur
current
effect
target
treatment
option
viral
titer
nasopharyng
aspir
infect
individu
peak
day
postinfect
provid
opportun
postexposur
treatment
includ
passiv
immunotherapi
antisarscov
human
monoclon
antibodi
hmab
spike
protein
cov
mediat
bind
fusion
event
necessari
infect
major
target
protect
immun
although
protein
sarscov
share
littl
amino
acid
ident
approxim
share
common
structur
featur
protein
cov
sarscov
protein
type
transmembran
glycoprotein
approxim
amino
acid
length
divid
two
function
domain
amino
acid
amino
acid
figur
mani
cov
protein
cleav
biogenesi
two
function
domain
held
togeth
noncoval
howev
like
hcov
protein
cleav
sarscov
domain
form
globular
structur
mediat
interact
protein
receptor
angiotensinconvert
enzym
region
consist
amino
acid
amino
acid
minim
receptor
bind
domain
rbd
figur
five
cystein
residu
within
rbd
import
effici
express
rbd
format
rbd
structur
three
function
glycosyl
site
within
rbd
locat
amino
acid
express
protein
requir
glycosyl
least
one
site
howev
glycosyl
affect
bind
cocrystal
rbd
human
identifi
concav
surfac
consist
amino
acid
contact
tip
defin
receptor
bind
motif
rbm
figur
basic
residu
found
amino
acid
appear
import
mediat
entri
pseudotyp
viru
alter
either
two
basic
residu
within
domain
abolish
pseudoviru
entri
howev
effect
mutat
may
due
decreas
protein
express
interestingli
none
eight
basic
residu
within
rbm
includ
alter
clinic
isol
figur
two
residu
identifi
critic
bind
chang
rbm
name
figur
might
allow
effici
bind
human
domain
mediat
fusion
contain
put
fusion
peptid
two
conserv
helic
region
upon
cleavag
endosom
proteas
cathepsin
l
form
six
helix
bundl
fusion
core
figur
two
region
connect
long
amino
acid
interdomain
loop
like
allow
flexibl
facilit
fusion
domain
form
inner
helic
coil
coil
region
onto
domain
associ
antiparallel
manner
form
fusion
core
bring
put
fusion
peptid
close
proxim
transmembran
domain
facilit
juxtaposit
cellular
viral
membran
requir
fusion
therapi
disrupt
interact
domain
would
like
confer
protect
synthet
peptid
demonstr
block
sarscov
infect
howev
peptid
found
inhibit
entri
ab
target
disrupt
viral
entri
discuss
cellular
glycoprotein
lsign
also
found
type
ii
pneumocyt
describ
altern
receptor
coreceptor
sarscov
infect
mediat
lsign
albeit
significantli
lower
effici
demonstr
nonpermiss
cell
residu
import
interact
lsign
vari
defin
rbd
sever
residu
map
ntermin
rbd
neutral
ab
interrupt
associ
fail
prevent
lsign
mediat
entri
interact
protein
dendrit
cellspecif
grab
nonintegrin
dcsign
facilit
entri
sarscov
via
interact
domain
protein
amino
acid
within
minimum
rbd
ntermin
rbm
dcsign
also
implic
abil
dendrit
cell
dc
transfer
sarscov
target
cell
vitro
without
product
infect
dc
similar
hiv
humor
immun
respons
appear
play
primari
role
recoveri
sarscov
infect
sarscov
induc
neutral
ab
primarili
target
rbd
posit
correl
diseas
outcom
infect
individu
dna
vaccin
studi
balbc
mice
show
antibodi
ab
respons
respons
reduc
viral
replic
passiv
transfer
immun
serum
mice
confer
protect
sarscov
challeng
deplet
cell
affect
vaccin
protect
adopt
transfer
cell
immun
mice
fail
protect
mice
sarscov
challeng
studi
demonstr
import
ab
clearanc
sarscov
infect
potenti
util
passiv
immunotherapi
sarscov
three
main
way
ab
elicit
protect
activ
neutral
opson
complement
activ
sever
mechan
describ
neutral
virus
ab
ab
may
aggreg
virus
prevent
bind
entri
bind
viral
attach
protein
cellular
receptor
prevent
entri
prevent
conform
chang
necessari
fusion
destabil
viru
caus
releas
viral
nucleic
acid
outsid
cell
prevent
uncoat
viru
capsid
prevent
releas
progeni
viru
infect
cell
constant
c
region
ab
contribut
viral
clearanc
opson
complement
activ
howev
ab
depend
enhanc
ade
infect
may
occur
uptak
viral
particl
via
complement
receptor
fc
receptor
fcr
ade
demonstr
group
cov
felin
infecti
periton
viru
fipv
evid
suggest
ade
may
occur
sarscov
discuss
pharmaceut
develop
mab
expand
greatli
provid
power
mode
therapeut
intervent
highli
specif
treatment
particularli
import
virus
neutral
ab
respons
import
protect
describ
sarscov
mous
mab
target
human
cell
first
approv
therapeut
use
prevent
kidney
transplant
reject
howev
treat
individu
develop
immun
respons
mous
c
region
limit
use
circumv
therapeut
chimer
hmab
produc
tabl
current
hmab
gener
use
sever
strategi
includ
prepar
hybridoma
use
transgen
mous
phage
display
technolog
immort
convalesc
b
cell
tabl
three
strategi
use
produc
hmab
sarscov
use
human
immunoglobulin
transgen
mous
eg
xenomous
allow
product
high
affin
hmab
hybridoma
fusion
immun
mous
immunoglobulin
gene
undergo
affin
matur
due
somat
hypermut
addit
transgen
mice
avail
five
immunoglobulin
class
allow
select
appropri
c
region
requir
mediat
particular
function
human
mab
may
also
gener
immunoglobulin
cdna
librari
correspond
immunoglobulin
variabl
v
region
howev
recombin
hmab
gener
cdna
librari
undergon
affin
matur
low
affin
monoclon
ab
produc
bacteria
unlik
fulli
glycosyl
usual
contamin
lipopolysaccharid
lp
desir
human
use
therefor
recombin
hmab
requir
express
mammalian
cell
mention
limit
overcom
use
memori
b
cell
obtain
convalesc
patient
like
undergon
affin
matur
immort
memori
b
cell
ebv
use
gener
hmab
sarscov
avian
influenza
cell
transform
ebv
presenc
polyclon
activ
cpg
oligonucleotid
significantli
increas
effici
immort
memori
b
cell
immunoglobulin
gene
sequenc
analysi
sarscov
specif
hmab
gener
use
xenomous
indic
preferenti
usag
certain
heavi
h
chain
gene
gene
famili
light
l
chain
gene
sarscov
specif
nonimmun
singlechain
variabl
antibodi
fragment
scfv
isol
phage
display
also
show
preferenti
usag
gene
famili
neutral
hmab
sarscov
bound
rbd
rbd
also
domin
domain
recogn
ab
infect
patient
neutral
hmab
target
ntermin
amino
acid
ctermin
rbd
amino
acid
close
junction
domain
amino
acid
within
domain
report
addit
mous
mab
interrupt
captur
pseudotyp
viru
dcsign
reduc
transinfect
also
report
two
strain
transgen
mice
use
produc
hmab
sarscov
differ
strain
mice
mous
l
chain
gene
still
function
medarex
humabmous
therefor
mice
produc
chimer
mab
xenomous
amgen
mous
l
chain
gene
delet
b
cell
produc
human
ab
immun
xenomous
recombin
protein
ectodomain
result
identif
sarscov
neutral
hmab
specif
hmab
fell
one
eight
group
determin
differ
bind
protein
fragment
immunoglobulin
gene
sequenc
major
specif
neutral
ab
react
rbd
howev
one
mab
react
ntermin
rbd
amino
acid
figur
immun
humab
mice
result
product
hybridoma
two
neutral
mab
evalu
monoclon
ab
map
rbd
recogn
epitop
contain
amino
acid
figur
tabl
monoclon
ab
chimer
mab
express
mous
light
chain
map
amino
acid
ntermin
rbd
figur
tabl
monoclon
ab
given
prophylact
reduc
viral
titer
lung
mice
limit
detect
reduc
viral
titer
patholog
lung
golden
syrian
hamster
given
post
infect
tabl
screen
immun
nonimmun
scfv
librari
also
use
gener
sarscov
specif
hmab
screen
nonimmun
scfv
librari
use
whole
viru
recombin
protein
led
identif
sarscov
specif
ab
one
eight
domain
specif
ab
mab
neutral
sarscov
demonstr
time
neutral
capac
monoval
scfv
tabl
mab
recogn
glycosyl
independ
epitop
within
amino
acid
protein
figur
tabl
three
four
specif
neutral
scfv
identifi
van
den
brink
et
al
recogn
overlap
conform
epitop
within
rbd
mab
demonstr
strongest
affin
figur
mab
bound
recombin
rbd
protein
repres
isol
variant
also
abl
reduc
viral
titer
lung
infect
ferret
prevent
viral
shed
nasopharynx
patholog
lesion
lung
tabl
immort
b
cell
convalesc
patient
yield
sever
neutral
hmab
react
rbd
mab
could
divid
six
group
base
differenti
neutral
sarscov
variant
hmab
decreas
viral
titer
lung
infect
mice
group
vi
mab
demonstr
protect
lethal
challeng
mous
model
tabl
rbd
specif
hmab
neutral
block
protein
bind
howev
neutral
ab
bound
within
rbd
appear
use
mechan
inhibit
rbd
specif
hmab
exampl
hmab
identifi
independ
scfv
librari
inhibit
receptor
bind
tabl
interestingli
hmab
enhanc
bind
protein
strain
isol
surfac
target
cell
still
neutral
identif
neutral
hmab
bind
ntermin
rbd
mab
mab
led
interest
insight
function
region
identif
epitop
distant
rbd
presenc
neutral
epitop
demonstr
import
yet
undefin
role
region
sarscov
entri
hmab
prevent
associ
protein
cellular
receptor
tabl
delet
within
first
amino
acid
elimin
fusion
abil
protein
celltocel
fusion
assay
maintain
receptor
bind
function
ntermin
region
protein
also
seem
play
role
trimer
protein
structur
may
requir
fusion
therefor
bind
hmab
region
may
interfer
viru
fusion
anoth
potenti
role
region
may
interact
unidentifi
coreceptor
requir
entri
may
disrupt
interact
protein
lsign
comparison
mab
specif
nonneutr
ab
identifi
screen
could
elucid
role
region
viral
entri
studi
hmab
reveal
prevent
postbind
step
viral
entri
addit
hmab
post
viru
bind
cell
effici
neutral
pseudotyp
viru
entri
import
discoveri
inclus
hmab
therapeut
cocktail
allow
target
one
entri
step
reactiv
hmab
also
play
import
role
inhibit
viral
entri
screen
fulllength
reactiv
nonreact
hmab
produc
xenomous
result
identif
neutral
ab
ab
may
recogn
epitop
within
domain
may
neutral
inhibit
fusion
domain
conserv
domain
therefor
region
reactiv
hmab
combin
distinct
reactiv
hmab
may
effect
wide
rang
clinic
isol
furthermor
would
interest
test
specif
hmab
zoonot
sarscov
isol
bat
sarslikecov
isol
determin
possibl
crossreact
appear
littl
crossreact
human
sarscov
bat
sarslikecov
isol
like
due
larg
differ
rbd
howev
neutral
human
bat
chimera
pseudotyp
viru
demonstr
crossneutr
potenti
outsid
rbd
immunoglobulin
gene
sequenc
xenomous
hmab
identifi
eight
uniqu
ab
group
recogn
conform
epitop
within
rbd
similarli
panel
hmab
gener
immort
convalesc
patient
b
cell
may
divid
six
group
base
abil
neutral
isol
earli
middl
late
phase
sar
outbreak
zoonot
isol
minor
alter
rbd
structur
could
result
loss
conform
epitop
allow
neutral
escap
cognat
hmab
examin
sequenc
clinic
isol
demonstr
chang
within
rbd
protein
toler
figur
interestingli
major
chang
rbd
alanin
scan
result
signific
loss
receptor
bind
demonstr
flexibl
protein
escap
immunolog
pressur
without
lose
infect
furthermor
singl
amino
acid
chang
within
protein
abolish
neutral
given
mab
monoclon
ab
gener
late
isol
may
effect
earli
zoonot
isol
may
lead
enhanc
infect
demonstr
increas
entri
mediat
pseudoviru
bear
protein
palm
civet
isol
hmab
therefor
neutral
hmab
bind
conserv
epitop
express
wide
rang
isol
best
candid
passiv
immunotherapi
escap
mutant
aris
viru
grown
presenc
hmab
sever
escap
mutant
sarscov
select
earli
passag
presenc
neutral
quantiti
xenomous
hmab
escap
mutant
also
appear
later
passag
presenc
subneutr
amount
hmab
escap
mutant
found
viru
grown
passag
presenc
hmab
escap
mutant
singl
amino
acid
chang
aros
presenc
hmab
hmab
produc
escap
mutant
zoonot
isol
viru
grown
presenc
hmab
develop
nonimmun
scfv
librari
also
yield
escap
mutant
singl
amino
acid
chang
viru
grown
presenc
hmab
gener
immun
scfv
librari
yield
escap
mutant
inabl
gener
escap
mutant
presenc
certain
hmab
would
suggest
region
critic
viru
infect
howev
demonstr
hmab
variant
also
escap
neutral
hmab
use
select
howev
escap
variant
gener
presenc
one
ab
could
neutral
differ
hmab
combin
hmab
find
highlight
import
use
mixtur
hmab
may
neutral
wide
rang
variant
differ
mechan
target
differ
epitop
passiv
immunotherapi
hmab
identifi
inhibit
postbind
step
viral
entri
bind
ntermin
rbd
mab
studi
combin
rbd
specif
hmab
use
pseudotyp
viru
use
combin
hmab
increas
efficaci
neutral
individu
hmab
increas
efficaci
confirm
neutral
assay
sarscov
similarli
hmab
demonstr
synergi
use
combin
neutral
sarscov
interestingli
combin
effect
escap
viru
alon
howev
certain
combin
hmab
yield
increas
efficaci
ideal
design
therapeut
cocktail
prevent
competit
hmab
allow
hmab
work
togeth
increas
inhibit
beyond
seen
individu
hmab
addit
examin
activ
mab
combin
may
identifi
possibl
candid
may
engin
gener
higher
affin
ab
mab
modifi
broaden
neutral
capabl
use
two
method
light
chain
shuffl
focus
mutagenesi
mutat
within
protein
found
render
mab
ineffect
crystal
structur
bound
sarscov
rbd
reveal
key
residu
region
light
chain
like
play
role
loss
neutral
amino
acid
mutat
region
identifi
hot
spot
activationinduc
cytidin
deaminas
aid
target
gener
hmab
broader
reactiv
method
identifi
sever
hmab
capabl
broader
neutral
demonstr
abil
neutral
late
isol
isol
isol
chang
examin
differ
rel
bind
affin
neutral
effici
hmab
allow
engin
higher
affin
hmab
approach
may
appli
promis
hmab
target
rna
viru
like
sarscov
import
consid
mutabl
viru
target
caus
primarili
error
prone
rnadepend
rna
polymeras
despit
unusu
larg
rna
genom
cov
nearli
error
frequenc
similar
note
rna
virus
predict
incorpor
chang
per
genom
per
replic
cycl
interestingli
cov
tend
restrict
host
tropism
howev
propens
acquir
mutat
facilit
host
jump
alter
tissu
tropism
seen
emerg
porcin
respiratori
viru
prcov
respiratori
variant
tgev
anoth
genet
tool
cov
abil
recombin
demonstr
abil
infecti
bronchiti
viru
ibv
isol
recombin
vaccin
strain
field
therefor
therapi
target
rna
virus
must
consid
quasispeci
natur
viral
popul
abil
viru
recombin
well
rapid
abil
rna
virus
mutat
respons
environment
pressur
sequenc
analys
escap
mutant
gener
combin
test
demonstr
care
examin
hmab
work
togeth
import
aspect
ration
therapeut
cocktail
design
infect
sarscov
human
immun
transgen
mice
result
product
mainli
nonneutr
ab
concern
sarscov
potenti
ade
infect
seen
fipv
enhanc
hepat
found
ferret
previous
vaccin
modifi
vaccinia
ankara
express
protein
upon
sarscov
challeng
addit
previou
studi
use
mous
immun
sera
well
sever
neutral
hmab
demonstr
hmab
enhanc
infect
pseudotyp
viru
express
palm
civet
protein
vitro
interestingli
vaccin
cdna
encod
ectodomain
sarscov
protein
elimin
enhanc
infect
palm
civet
pseudotyp
viru
import
note
xenomous
humabmous
immun
ectodomain
protein
unlik
hmab
produc
gener
xenomous
isotyp
advantag
isotyp
includ
failur
activ
classic
complement
pathway
low
affin
fcr
macrophag
phagocyt
therefor
hmab
less
like
facilit
ade
addit
concern
possibl
cross
reactiv
antisar
ab
self
antigen
serum
sampl
sar
patient
contain
ab
crossreact
epitop
lung
epitheli
cell
caus
cytotox
vitro
ab
react
predominantli
two
defin
epitop
within
amino
acid
epitop
within
protein
avail
sever
neutral
ab
allow
select
recogn
crossreact
selfepitop
human
mab
quickli
becom
desir
therapeut
option
sinc
addit
seven
mab
brought
market
six
develop
use
hmab
technolog
tabl
adalimumab
develop
phage
display
technolog
first
fulli
hmab
use
therapeut
target
treat
varieti
autoimmun
disord
sever
year
later
anoth
hmab
panitumumab
gener
use
transgen
mice
approv
treatment
egfrexpress
colorect
cancer
major
therapeut
mab
indic
treatment
cancer
varieti
autoimmun
diseas
current
one
human
mab
approv
treatment
infecti
diseas
tabl
rsv
infect
known
caus
signific
infant
morbid
mortal
success
prevent
human
antirsv
ab
palivizumab
given
prophylact
palivizumab
gener
insert
v
region
mous
mab
human
igg
framework
rapid
clearanc
reduc
efficaci
advers
reaction
seen
chimer
human
ab
differ
speci
may
substanti
avoid
use
hmab
often
neutral
ab
use
passiv
therapi
like
blunt
viru
replic
allow
innat
adapt
immun
system
suffici
time
mount
immun
respons
antibodi
proven
import
respons
sarscov
recov
patient
show
higher
ab
titer
neutral
ab
protein
maintain
limit
retrospect
studi
sarscov
patient
report
administr
convalesc
patient
serum
protect
infect
advers
event
indic
passiv
therapi
could
safe
effect
treatment
ab
neutral
vitro
usual
also
confer
vivo
protect
result
reduc
viral
titer
hmab
review
candid
passiv
immunotherapi
provid
immedi
protect
individu
may
expos
sarscov
due
reemerg
laboratori
exposur
emerg
sarscov
result
rapid
product
sever
group
hmab
therapeut
potenti
highlight
techniqu
may
use
gener
hmab
emerg
virus
cov
current
circul
bat
speci
care
studi
sarscov
protein
specif
hmab
contribut
greater
understand
sarscov
infect
highlight
potenti
util
hmab
immunotherapeut
agent
also
molecular
biolog
tool
antibodi
minimum
region
respons
bind
rbm
receptor
bind
motif
specif
region
contact
fp
fusion
peptid
helic
repeat
domain
involv
fusion
monoclon
ab
identifi
react
indic
region
rbd
specif
base
mutat
identifi
escap
variant
influenc
mutat
identifi
escap
variant
protein
sequenc
sarscov
clinic
isol
align
use
jelllyfish
softwar
chang
within
domain
depict
repres
isol
magnif
highlight
chang
within
rbd
box
highlight
amino
acid
fall
within
defin
rbm
monoclon
ab
current
approv
treatment
march
tabl
compris
complet
mab
includ
fab
fragment
monoclon
therapi
discontinu
diagnost
mab
approv
monoclon
ab
infecti
diseas
palivizumab
may
given
prophylact
prevent
seriou
rsv
infect
risk
infant
first
human
monoclon
ab
approv
follow
approv
first
human
monoclon
ab
produc
transgen
mice
treat
colorect
cancer
subsequ
numer
human
monoclon
ab
produc
use
transgen
mice
display
technolog
target
varieti
autoimmun
diseas
cancer
osteoporosi
sever
techniqu
util
gener
human
monoclon
ab
target
protein
sarscov
tabl
provid
summari
group
mab
sarscov
includ
method
use
gener
efficaci
mechan
action
antibodi
class
anim
model
mechan
action
